The Indian rupee traded in a narrow band against the US dollar as mixed global signals kept currency traders cautious. Dollar movement, crude oil prices and foreign fund flows remained key drivers for the domestic unit.
The Indian rupee traded in a narrow band against the US dollar as mixed global signals kept currency traders cautious. Dollar movement, crude oil prices and foreign fund flows remained key drivers for the domestic unit.
Midcap and smallcap segments witnessed selective accumulation even as frontline indices remained under pressure. Investors showed interest in fundamentally strong counters after the recent correction in the broader market.
Gold prices firmed up in domestic markets supported by safe-haven demand and global uncertainty. Weakness in the dollar and cautious equity sentiment also aided the yellow metal’s upward bias.
The Nifty 50 managed to hold crucial support levels during the session, though overall sentiment remained cautious. Intraday volatility persisted as investors booked profits in high-beta sectors.
Indian equity benchmarks witnessed a volatile session with the Sensex ending lower amid broad-based profit booking. Selling pressure in IT, metals and select financial stocks dragged the index despite intermittent buying support in banking counters.
Capital goods firms continue to report robust order inflows driven by investments in power, railways and industrial capex. Order books across several engineering players remain at multi-year highs, indicating strong demand visibility.
FMCG firms are closely monitoring rural demand trends, which are showing early signs of stabilisation after a muted phase. Improved monsoon patterns and government support measures are expected to aid rural consumption.
Cement manufacturers are preparing for improved dispatch volumes supported by ongoing infrastructure activity and government spending. Demand visibility remains healthy across roads, urban infrastructure and housing segments.
Indian pharmaceutical firms are expanding their product pipeline in the US generics market, with multiple ANDA approvals and specialty filings underway. Companies are increasingly targeting complex generics and niche therapies to improve profitability.
Public sector banking firms are witnessing a steady improvement in asset quality, supported by lower slippages and strong recovery momentum. Gross NPAs across major lenders have continued to trend downward, reflecting disciplined underwriting and better credit monitoring.
For those of you who are serious about having more, doing more, giving more and being more, success is achievable with some understanding of what to do.
